Current Events

At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions. Headlines proclaimed a potential game changer in treating cardiovascular disease. And company shares quickly soared, from $3 a share to about $20.

Vascepa is Amarin’s only product. The company wants to turn its pill made of purified fish oil into a cash cow, allowing it to staff up both in the United States and abroad so it can sell doctors and millions of consumers on its medical benefits. Although the product has been on the market for more than five years, its first TV ad campaign rolled out this summer in anticipation of the study findings.

Read More

Subaru and Toyota are recalling about 165,000 U.S. vehicles they manufactured jointly after discovering a defect that could lead to the engine stalling in rare cases.

The affected vehicles were assembled by Subaru at a joint venture operation in Japan.

The recall covers about 140,000 Subaru vehicles in the U.
Read more . . .

(CNN)The US Food and Drug Administration is not doing enough to prevent medical devices such as pacemakers and insulin pumps from being hacked, a report from the US Department of Health and Human Services' Office of the Inspector General said Thursday.

"FDA had plans and processes for addressing certain medical device problems in the postmarket phase, but its plans and processes were deficient for addressing medical device cybersecurity compromises," the report says.

Read more . . .

The US Food and Drug Administration is alerting patients of another recall of medicine used to treat high blood pressure, for a potential cancer risk due to contamination. This time, SciGen is recalling certain lots of irbesartan.

The recalled lot will have "Westminster Pharmaceuticals" and "GSMS Inc." on the label, according to the FDA list.
Another heart medicine, valsartan, has also been recalled recently due to contamination.

Read More

(Reuters) - A proposed class action lawsuit in San Francisco federal court accuses Wells Fargo of making tens of thousands of automatically dialed, or “robo,” calls to cell phones without consumers’ consent.

Filed on Thursday on behalf of a nationwide class, the lawsuit accuses Wells Fargo of calling wrong numbers with auto-dialing equipment and failing to honor requests to stop. The complaint seeks triple damages under the U.S. Telephone Consumer Protection Act, or up to $1,500 for each call.

Read More

Four pharmacy benefit managers must face a lawsuit alleging they breached their duties as administrators of employee health insurance plans’ drug benefits by causing Mylan NV to raise the EpiPen allergy medication’s price, a federal judge has ruled.

U.S. District Judge Paul Magnuson in St. Paul, Minnesota on Friday denied motions by CVS Health Corp, Express Scripts Holdings, UnitedHealth Group Inc and Prime Therapeutics to dismiss a proposed class action by participants in employee health insurance plans.

Read More

Earlier this year, the Centers for Disease Control and Prevention released a stunning statistic. Seventy-two thousand people, it estimates, died of drug overdoses in 2017. The huge increase in deaths is largely due to heroin and powerful synthetic opioids like fentanyl.

One of the tools being used to fight that wave of deaths is the drug naloxone. It's been called the Lazarus drug for its ability to revive people dying from overdoses. It can be injected or simply administered through a nasal spray. (The spray form of the drug is known by the brand name Narcan.)

Read More

WASHINGTON (Reuters) - Wells Fargo & Co will not finish paying back the estimated 600,000 customers it wrongly charged for auto insurance until at least 2020, the bank said in a letter to U.S. lawmakers seen by Reuters.

U.S. regulators slapped Wells Fargo with a $1 billion penalty in April when it admitted to wrongly forcing drivers into auto insurance policies. That agreement envisioned the customer payouts would finish within months.

Read More

The Food and Drug Administration is poised to approve a new form of a powerful opioid for use in hospitals and emergency rooms despite opposition from the head of the committee that reviewed the drug.

The FDA is scheduled to decide by Nov. 3 whether to allow a California company to produce a 30-microgram pill form of sufentanil, a potent painkiller commonly used after surgery.

Federal regulators are investigating Mercedes-Benz over whether it was too slow to mail out notices for a recall of 1.4 million cars in 2017.

The National Highway Traffic Safety Administration sent the German carmaker a 14-page letter asking it to explain why customers weren’t informed of the recall within the federally mandated time period.

The threat posed by the overuse of antibiotics is becoming increasingly worrying. Last week, a Public Health England report warned that antibiotic-resistant superbugs – resulting from prolific prescriptions – are now killing more than 2,500 Britons every year.